Navigation Links
Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products
Date:8/20/2009

s programs, Synthes' success in selling Kensey Nash's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of Kensey Nash's products and competition from other technologies.

In addition, changes in competitive conditions and regulatory developments may affect future business performance, and changing market conditions may affect the valuation of the Companies' securities. In addition, it should be noted that past financial and operational performance of the Companies is not necessarily indicative of future financial and operational performance.

The Companies undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For a detailed discussion of factors that could affect Kensey Nash's future operating results, please see Kensey Nash's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

The securities of Synthes have been offered and sold outside the United States and have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"). Such securities may not be offered, sold or transferred in the U.S. or to U.S. Persons (as defined in the regulations of the Securities Act), except pursuant to a registration statement filed under the Securities Act or under an applicable exemption under the Securities Act. Hedging transactions involving such securities may not be conducted unless in compliance with the Securities Act. The Synthes securities are deemed "Restricted Securities" as that term is defined in R
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Synthesis and Purification of Peptide Libraries -- Innovative Approaches
2. Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training
3. Does Synthetic Biology Need Synthesized Ethics?
4. METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis (SPPS)
5. Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
6. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
7. Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.
8. Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library
9. Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
10. Scientists synthesize memory in yeast cells
11. Scientists synthesize memory in yeast cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that ... that it has completed its previously announced private placement ... of 5,000,000 shares of common stock and five-year warrants ... for aggregate gross proceeds of $2.5 million.   ...
... June 23, 2011 ,   ... science consulting,has published an insight into the future development ... out a,vision of how the industry may look as ... reflects on the decisions it has made.,In particular, Alacrita ...
... June 22, 2011 Wound Management Technologies, Inc., (OTCQB: ... solutions today announced that Company President Deborah Jenkins Hutchinson, ... OneMedForum NY Conference on Thursday, June 23, 2011 at ... 45 East 45 St. in New York City. The ...
Cached Biology Technology:Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 2Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 3Alacrita Asks "Are We All Biotech Now?" 2Alacrita Asks "Are We All Biotech Now?" 3Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 2Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 3
(Date:7/10/2014)... partners predict that western Lake Erie will have a ... the 2014 bloom season in late summer. However, the ... year,s intense bloom, and considerably less than the record-setting ... lake,s western basin and are classified by an estimate ... , Harmful algal blooms (HABs) were common in ...
(Date:7/10/2014)... Clarksburg, MDBrightFocus Foundation, a nonprofit organization funding cutting-edge, ... diseases of glaucoma and macular degeneration, today announced ... to 55 scientists in 19 U.S. states, the ... http://www.brightfocus.org/Grants2014 . , With these latest ... million in research funding in 2014. , The ...
(Date:7/10/2014)... collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spot, which appears as a red mark, is an ... recognized temperatures higher than background. When accompanied by plumes ... are diagnostic for fire. , This area of ... from the fires, although the smoke released by any ...
Breaking Biology News(10 mins):NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 3BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3
... University of Leicester and part-funded by The Leverhulme Trust aims ... By bringing together an artist and a neuroscientist, both ... perception. In the process of the research, both artist and ... the eye of the beholder. Rodrigo Quian Quiroga, Neuroscientist ...
... opinion that inflammation in adipose tissue may cause insulin resistance, ... Swedish medical university Karolinska Institutet, published in the New ... in the body fat is only pernicious. Instead the findings ... necessary for fat cell turnover in the lean, healthy state. ...
... not just thinking big but also very, very, very ... director of Binghamton University,s Center for Advanced Sensors and ... that would detect and identify engineered nanoparticles. Her research ... the environmental release and transformation of these particles. ...
Cached Biology News:Beauty is in the eye of the beholder? 2Inflammation in body fat is not only pernicious 2Chemist monitors nanotechnology's environmental impact 2
... Highly-purified, endotoxin-free plasmid DNA preparations are ... in quantities from 1mg to multi-gram ... as large-scale (100mg-multi-gram) preparations are made ... preparation is formulated according to customer ...
... operate as a Voltage Clamp, as a Current ... electrophysiology research applications. Performance in any one ... This amazing instrument is made possible by ... Signal Processing (DSP) integrated circuit chips. Until very ...
... Ph.D. Peptide Display Cloning System facilitates the ... surface of bacteriophage M13 as coat protein ... displayed peptide and its encoding DNA sequence. ... can then be selected by the straightforward ...
... cell culture or fermentation is the ability ... and make rapid adjustments in response to ... Analyzers provide immediate analysis of key nutrients, ... fermentation media. BioProfile analyzers are fully automated, ...
Biology Products: